Motus GI Hlds

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in 2008 and is headquartered in Fort Lauderdale, FL.

- Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - - On track to submit a 510(k) to the U.S. FDA for the Pure-Vu Gen 4 Gastro device in Q4 2023 to support the 400,000 upper GI bleeds and other procedures with impaired visualization in the U.S. - - Pure-Vu Gen 4 Gastro to be used during the 9 th IECED Live Endoscopy Course 2023 through the Pentax Learning Center in June 2023 - FORT LAUDERDALE, Fla., May 17, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced in collaboration with the Ecuadorian Institute of Digestive Diseases (IECED) initiation of a clinical evaluation of the Pure-Vu Gen 4 Gastro, which is designed for upper gastrointestinal (GI) bleeding procedures - an area of high unmet patient need.

Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission

Motus GI Holdings, Inc. (MOTS) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.80 per share a year ago.

Motus GI Holdings, Inc. (MOTS) Reports Q1 Loss, Lags Revenue Estimates

■ Oral presentation at the Digestive Disease Week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (IBP)in just six months after implementation of the Pure-Vu® system at the Minneapolis VA Medical Center         ■ The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures - an area of high unmet patient need - and expects submission of the 510(k) to the FDA for this new product line and its next generation Lower GI platform in Q4 2023         ■ The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Motus GI Reports First Quarter 2023 Financial Results and Provides Corporate Update

FORT LAUDERDALE, Fla. , April 13, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today announced executive changes and restructuring as part of its strategy to reduce operating costs while supporting key value creation drivers, including ongoing R&D efforts to bring Pure-Vu Upper GI, and an enhanced Lower GI platform to market, while continuing to support existing customer base and target pipeline opportunities in contracted health systems. As part of the executive changes, Mr. Moran has elected to step down as Chief Executive Officer (CEO) of the Company to pursue other business opportunities. Mr. Moran will remain on the Board and has been appointed Chairman of the Board, succeeding David Hochman, who will remain an independent director, effective immediately. Mark Pomeranz, the Company's current President, Chief Operating Officer, and director and former CEO of the Company, has been appointed as the Company's CEO, effective immediately. Mr. Moran will work closely with Mr. Pomeranz to support a smooth transition and maintain key relationships with Motus GI's stakeholders.

Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 36.80% and 72.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Lags Revenue Estimates

FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

FORT LAUDERDALE, Fla., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value and accelerating commercialization of the Pure-Vu System. As part of this process, the Company has engaged Lake Street Capital Markets LLC to act as an advisor to the Company in this process.

Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan

Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 9.63% and 14.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Misses Revenue Estimates

Motus GI Holdings, Inc. (NASDAQ:MOTS ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Garth Russell - Managing Director-LifeSci Advisors, LLC Tim Moran - Chief Executive Officer Andrew Taylor - Chief Financial Officer Mark Pomeranz - President & Chief Operating Officer Conference Call Participants Steve Lichtman - Oppenheimer and Co. Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by, and welcome to the Motus GI Holdings, Inc. Third Quarter 2022 Financial and Operational Update. At this time, all participants are in a listen-only mode.

Motus GI Holdings, Inc. (MOTS) Q3 2022 Earnings Call Transcript

FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update

FORT LAUDERDALE, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its third quarter financial results on Monday, November 14, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Third Quarter Results and Provide a Business Update on November 14

Applied Genetic Technologies

Imperial Petroleum

Nokia

Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Make Money With Penny Stocks in November? 3 Methods to Use

FORT LAUDERDALE, Fla., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that three abstracts featuring clinical data on the Pure-Vu EVS were presented in poster sessions at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held October 21 to 26, 2022 in Charlotte, North Carolina. The three abstracts will be published on the Motus GI Website: https://motusgi.com/physicians-nurses/clinical-evidence/.

Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

Arlo Technologies Inc

Borr Drilling Ltd

Penny stocks are companies that generally trade under $5 per share or have very low trading volume. They are also companies many investors ignore.

3 Penny Stock Predictions for 2023

Source: ArtemisDiana/Shutterstock In yet another topsy-turvy session in the markets, investors may want to look for bright spots in this uncertain time. One of today's biggest winners is Motus GI (NASDAQ: MOTS ), a maker of colonoscopy-related medical devices and technologies.

Why Is Motus GI (MOTS) Stock Up 50% Today?

Motus GI Holdings, Inc. (MOTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Motus GI Holdings, Inc. (MOTS) Upgraded to Buy: What Does It Mean for the Stock?

Agenus

Addentax Group Corp

Grab Holdings Ltd

Toughbuilt Industries Inc

5 top penny stocks to buy for under $5 but are they worth the risk? The post Top Penny Stocks To Buy Now?

Top Penny Stocks To Buy Now? 5 To Watch Under $5 Today

FORT LAUDERDALE, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11446428) titled, “Cleaning Method for Prepless Colonoscopy.”

Motus GI Granted a U.S. Patent for Prepless Colonoscopy Methods Embodied by the Pure-Vu® System

FORT LAUDERDALE, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today it is now officially recognized as a sole source provider and small business by the Veterans Health Administration (VHA), the largest integrated health care system in the U.S. providing care to over nine million veterans. These special designations provide the Company with direct access to the VHA's procurement arm, thereby streamlining the purchasing and contracting process. The Company believes this will increase its ability to access VA medical centers across the country and increase the use of the of Pure-Vu EVS System to help veterans suffering from inadequate pre-procedural bowel preparation for both inpatient and outpatient colonoscopies.

Motus GI Named a Sole Source Supplier with U.S. Department of Veteran Affairs

Motus GI Holdings, Inc. (NASDAQ:MOTS ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Garth Russell - Managing Director-LifeSci Advisors, LLC Tim Moran - Chief Executive Officer Andrew Taylor - Chief Financial Officer Mark Pomeranz - President and Chief Operating Officer Conference Call Participants Steven Lichtman - Oppenheimer Benjamin Haynor - Alliance Global Partners Boobalan Pachaiyappan - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by and welcome to the Motus GI Holdings, Inc. Second Quarter 2022 Financial and Operational Update.

Motus GI Holdings, Inc. (MOTS) CEO Tim Moran on Q2 2022 Results - Earnings Call Transcript

FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today reported its financial results for the second quarter ended June 30, 2022, and provided a corporate update.

Motus GI Reports Second Quarter 2022 Financial Results and Provides Business Update

Motus GI Holdings, Inc. (MOTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Motus GI Holdings, Inc. (MOTS) Expected to Beat Earnings Estimates: Should You Buy?

FORT LAUDERDALE, Fla., July 25, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it will effect a 1-for-20 reverse stock split of its outstanding common stock. The Company's common stock will begin trading on a split-adjusted basis at the opening of the market on Tuesday, July 26, 2022. The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol “MOTS” and under the new CUSIP number, 62014P405.

Motus GI Announces 1-FOR-20 Reverse Stock Split

FORT LAUDERDALE, Fla., July 21, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter financial results on Thursday, August 11, 2022, after the market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on recent corporate developments.

Motus GI to Release Second Quarter Results and Provide a Business Update on August 11

– The Pure-Vu system improved the adequate cleansing rate more than 200% to 97.7% in patients with a history of poor bowel preparation

News for Motus GI Hlds Stock (MOTS)